Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 1-Year Low Following Analyst Downgrade

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares hit a new 52-week low on Thursday after Royal Bank Of Canada lowered their price target on the stock from $445.00 to $350.00. Royal Bank Of Canada currently has an outperform rating on the stock. Alnylam Pharmaceuticals traded as low as $225.49 and last traded at $220.3510, with a volume of 185433 shares changing hands. The stock had previously closed at $286.62.

ALNY has been the topic of several other reports. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Needham & Company LLC reduced their target price on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a report on Thursday. JPMorgan Chase & Co. decreased their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research note on Friday. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Oppenheimer lowered their price target on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $410.72.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Assenagon Asset Management S.A. boosted its stake in shares of Alnylam Pharmaceuticals by 20.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 155,695 shares of the biopharmaceutical company’s stock worth $46,869,000 after buying an additional 26,799 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 7.9% in the first quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 65 shares during the period. Glenmede Trust Co. NA increased its position in Alnylam Pharmaceuticals by 8.3% during the first quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 56 shares during the last quarter. Groupama Asset Managment lifted its holdings in Alnylam Pharmaceuticals by 2.5% in the first quarter. Groupama Asset Managment now owns 36,767 shares of the biopharmaceutical company’s stock valued at $12,165,000 after acquiring an additional 889 shares during the period. Finally, Segall Bryant & Hamill LLC purchased a new position in Alnylam Pharmaceuticals in the first quarter worth about $641,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

The firm has a 50-day simple moving average of $287.96 and a 200-day simple moving average of $311.32. The firm has a market capitalization of $27.44 billion, a PE ratio of 38.20 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 104.81%. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm earned ($0.44) EPS. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.35 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.